# Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

> **NCT04133909** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 806 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **BIOLOGICAL:** Mepolizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04133909
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-30
- **Primary completion:** 2024-08-08
- **Final completion:** 2024-08-08
- **Target enrollment:** 806 (ACTUAL)
- **Last updated:** 2025-08-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04133909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04133909, "Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04133909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*